ES2485615A1 - Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama - Google Patents

Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama Download PDF

Info

Publication number
ES2485615A1
ES2485615A1 ES201330179A ES201330179A ES2485615A1 ES 2485615 A1 ES2485615 A1 ES 2485615A1 ES 201330179 A ES201330179 A ES 201330179A ES 201330179 A ES201330179 A ES 201330179A ES 2485615 A1 ES2485615 A1 ES 2485615A1
Authority
ES
Spain
Prior art keywords
prognosing
predicting
breast
products
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201330179A
Other languages
English (en)
Other versions
ES2485615B1 (es
ES2485615B8 (es
Inventor
Francisco Javier FREIRE SALINAS
Javier GÓMEZ ROMÁN
Saioa DOMÍNGUEZ HORMAETXE
Laureano Simón Buela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomatryx Biopharma SL
Original Assignee
Oncomatryx Biopharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomatryx Biopharma SL filed Critical Oncomatryx Biopharma SL
Priority to ES201330179A priority Critical patent/ES2485615B8/es
Priority to US14/767,119 priority patent/US20150369808A1/en
Priority to ES14712327.7T priority patent/ES2628150T3/es
Priority to PCT/ES2014/070094 priority patent/WO2014125144A1/es
Priority to EP14712327.7A priority patent/EP2957913B1/en
Publication of ES2485615A1 publication Critical patent/ES2485615A1/es
Publication of ES2485615B1 publication Critical patent/ES2485615B1/es
Application granted granted Critical
Publication of ES2485615B8 publication Critical patent/ES2485615B8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Image Analysis (AREA)

Abstract

Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama. La presente invención se refiere a métodos y productos in vitro para pronosticar la evolución clínica o predecir el riesgo y tipo de recidiva de una lesión papilar de mama, en base a expresión de la proteína proCOL11A1, con el objetivo de determinar el tratamiento y patrón de seguimiento más adecuado para cada paciente.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
    imagen7
ES201330179A 2013-02-12 2013-02-12 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama Active ES2485615B8 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201330179A ES2485615B8 (es) 2013-02-12 2013-02-12 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama
US14/767,119 US20150369808A1 (en) 2013-02-12 2014-02-11 Methods and products for prognosing the clinical evolution, or predicting the recurrence risk, of a papillary lesion of the breast
ES14712327.7T ES2628150T3 (es) 2013-02-12 2014-02-11 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama
PCT/ES2014/070094 WO2014125144A1 (es) 2013-02-12 2014-02-11 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama
EP14712327.7A EP2957913B1 (en) 2013-02-12 2014-02-11 Methods and products for prognosing the clinical evolution, or predicting the recurrence risk, of a papillary lesion of the breast

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330179A ES2485615B8 (es) 2013-02-12 2013-02-12 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama

Publications (3)

Publication Number Publication Date
ES2485615A1 true ES2485615A1 (es) 2014-08-13
ES2485615B1 ES2485615B1 (es) 2015-04-27
ES2485615B8 ES2485615B8 (es) 2015-06-05

Family

ID=50349639

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201330179A Active ES2485615B8 (es) 2013-02-12 2013-02-12 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama
ES14712327.7T Active ES2628150T3 (es) 2013-02-12 2014-02-11 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14712327.7T Active ES2628150T3 (es) 2013-02-12 2014-02-11 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama

Country Status (4)

Country Link
US (1) US20150369808A1 (es)
EP (1) EP2957913B1 (es)
ES (2) ES2485615B8 (es)
WO (1) WO2014125144A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596813A4 (en) 2003-01-31 2008-02-20 Five Prime Therapeutics Inc POLYPEPTIDES EXPRESSED BY LUNGS
RU2473555C2 (ru) * 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных
EP2483813A1 (en) * 2009-10-01 2012-08-08 Chipdx LLC System and method for classification of patients
ES2398328B1 (es) 2011-08-09 2014-02-05 Oncomatrix, S.L. Métodos y productos para el diagnóstico in vitro, pronóstico in vitro y desarrollo de fármacos contra carcinomas invasivos.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FISCHER H. et al. Colorectal carcinogénesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogénesis. 2001. Vol. 22(6), páginas: 875-878. *
GARCIA OCAÑA M. et al. Characterization of a novel mouse monoclonal antibody, clone 1E8.33, highly specific for human procollagen 11A1, a tumor-associated stromal component. International Journal of Oncology. 2012, Vol. 40, páginas:1447-1454, página 1447, columnas 1-2; página 1452, columna 1, Figure 5; página 1452, columna 1. *
GARCIA PRAVIA C. et al. Anti-pro COLL11A1, a new marker of infiltrating breast cancer. ESSR Abstract 2009. British Journal of Surgery. 2009. Vol. 96(S5), páginas: 1-72, página 11, abstract O-05-4. *
KLEIN A. et al. Comparison of gene expression data from human and mouse breast cancers: Identification of a conserved breast tumor gene set. International Journal of Cancer. 2007, Vol. 121, páginas: 683-688, página 683, abstract; página 684, Figure 1; página 685, columna 2. *
ZHAO Y. et al. A Potential Role of Collagens Expression in Distinguishing Between Premalignant and Malignant Lesions in Stomach. The Anatomical Record. 2009. Vol. 292, páginas: 692-700, todo el documento. *

Also Published As

Publication number Publication date
ES2485615B1 (es) 2015-04-27
ES2485615B8 (es) 2015-06-05
EP2957913A1 (en) 2015-12-23
ES2628150T3 (es) 2017-08-01
EP2957913B1 (en) 2017-03-29
US20150369808A1 (en) 2015-12-24
WO2014125144A1 (es) 2014-08-21

Similar Documents

Publication Publication Date Title
SA517390218B1 (ar) جهاز وطرق لتحديد النسيج التالف باستخدام قياسات الرطوبة تحت الجلد
DOP2013000025A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CL2014002975A1 (es) Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
AR092423A1 (es) Metodo de diagnostico y tratamiento del cancer dirigido a las moleculas expresadas en celulas madre cancerosas
CY1122042T1 (el) Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο
CL2017000578A1 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia
MX2017006491A (es) Composiciones y métodos para la modulación de la actividad at2r.
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли
ES2485615A1 (es) Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama
WO2015092444A3 (en) Biomarkers
IT201600109735A1 (it) Biomarcatori e metodi per la diagnosi in vitro di sclerosi multipla.
RU2012144141A (ru) Способ оценки вероятности возникновенения переломов при остеопорозе у женщин
WO2016096640A3 (en) Anti-cxcl12 antibody molecules and their uses
ES2517190A1 (es) Linea celular de carcinoma inflamatorio mamario canino
UA36434S (uk) Калькулятор оцінки ризику розвитку першого інсульту у хворих на гіпертонічну хворобу дисковий
Оськина et al. TOURISM IN RUSSIA: PROBLEMS AND NEW OPPORTUNITIES
Baranova et al. Company’s marketing strategy in a view of its life cycle
Kaunitz et al. Atypical hyperplasia of the breast: Cancer risk-reduction strategies
UA122278U (uk) Спосіб прогнозування платинорезистентності та платинорефрактерності перед ад'ювантною хіміотерапією в хворих на епітеліальний рак яєчників за рибіним а.і.
UA117415U (uk) Спосіб лікування хворих на кондиломи періанальної області
UA118342U (uk) Спосіб оцінки функції лівого шлуночка серця у пацієнтів, що перенесли інфаркт міокарда
UA95129U (uk) Спосіб визначення ступеня ураження периферійного нерва при діабетичній периферійній полінейропатії
PL408307A1 (pl) Biomarkery w nieinwazyjnej diagnostyce prenatalnej aberracji chromosomowej Zespołu Downa

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: ONCOMATRIX BIOPHARMA, S.L.

Effective date: 20140416

FG2A Definitive protection

Ref document number: 2485615

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150427